Rani Therapeutics develops the RaniPill capsule, an oral delivery technology for drugs and biologics that are now often given by injection. RANI reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 22 | Chardan Capital | Maintained | Buy | |
| Aug 18 | Chardan Capital | Initiated | Buy | |
| May 20 | Canaccord Genuity | Maintained | Buy |
Seasonality
How RANI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in RANI in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RANI is in one of them and how their past RANI trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered RANI in an article yet. Here's the latest on the wider market.
About Rani Therapeutics Holdings
Rani Therapeutics is a biotherapeutics company based in San Jose, California. It is developing the RaniPill capsule, a delivery technology designed to let drugs and biologics such as antibodies and peptides be taken orally instead of by injection. The company is advancing its own oral drug candidates and is seeking partnerships with biopharmaceutical companies to use its technology. Its intended customers include patients, physicians, and healthcare systems, and it has no approved products for sale yet.
- Headquarters
- San Jose, CA